NASDAQ:PIRS - Pieris Pharmaceuticals Stock Price, Forecast & News

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) issued its quarterly earnings data on Monday, November, 11th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.23) by $0.18. The biotechnology company earned $15.13 million during the quarter, compared to analysts' expectations of $6.28 million. Pieris Pharmaceuticals had a negative return on equity of 132.02% and a negative net margin of 107.24%. View Pieris Pharmaceuticals' Earnings History.

Pieris Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Pieris Pharmaceuticals.

4 Wall Street analysts have issued 1 year price objectives for Pieris Pharmaceuticals' stock. Their forecasts range from $5.00 to $9.00. On average, they expect Pieris Pharmaceuticals' share price to reach $7.00 in the next year. This suggests a possible upside of 87.7% from the stock's current price. View Analyst Price Targets for Pieris Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pieris Pharmaceuticals.

Media stories about PIRS stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Pieris Pharmaceuticals earned a news impact score of -3.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Pieris Pharmaceuticals.

Pieris Pharmaceuticals saw a decline in short interest in January. As of January 31st, there was short interest totalling 1,180,000 shares, a decline of 32.6% from the January 15th total of 1,750,000 shares. Based on an average trading volume of 564,500 shares, the days-to-cover ratio is currently 2.1 days. Approximately 2.4% of the shares of the company are short sold. View Pieris Pharmaceuticals' Current Options Chain.

Some companies that are related to Pieris Pharmaceuticals include Intrexon (XON), Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), STARPHARMA HOLD/S (SPHRY), Auxly Cannabis Group (CBWTF), Luna Innovations (LUNA), Eloxx Pharmaceuticals (ELOX), Geovax Labs (GOVX), Bioanalytical Systems (BASI), BIOQUAL (BIOQ), HedgePath Pharmaceuticals (HPPI), Cleveland BioLabs (CBLI), Tenax Therapeutics (TENX), US Stem Cell (USRM) and Vitality Biopharma (VBIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Pieris Pharmaceuticals investors own include TG Therapeutics (TGTX), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Verastem (VSTM), Agile Therapeutics (AGRX), Inovio Pharmaceuticals (INO), Anavex Life Sciences (AVXL), Exelixis (EXEL), Nabriva Therapeutics (NBRV) and Sangamo Therapeutics (SGMO).

Pieris Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (3.61%), Candriam Luxembourg S.C.A. (2.71%), State Street Corp (1.79%), Parkman Healthcare Partners LLC (1.13%), Acadian Asset Management LLC (1.10%) and Oxford Asset Management LLP (0.77%). Company insiders that own Pieris Pharmaceuticals stock include Bvf Partners L P/Il, Christopher P Kiritsy, James A Geraghty and Orbimed Advisors Llc. View Institutional Ownership Trends for Pieris Pharmaceuticals.

PIRS stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Schonfeld Strategic Advisors LLC, Renaissance Technologies LLC, Goldman Sachs Group Inc., Spark Investment Management LLC, Alpine Global Management LLC, Meeder Asset Management Inc. and Massachusetts Financial Services Co. MA. View Insider Buying and Selling for Pieris Pharmaceuticals.

PIRS stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Parkman Healthcare Partners LLC, Marshall Wace North America L.P., Voss Capital LLC, Jacobs Levy Equity Management Inc., Panagora Asset Management Inc., Oxford Asset Management LLP and Marshall Wace LLP. Company insiders that have bought Pieris Pharmaceuticals stock in the last two years include Christopher P Kiritsy and James A Geraghty. View Insider Buying and Selling for Pieris Pharmaceuticals.

Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PIRS stock can currently be purchased for approximately $3.73.

Pieris Pharmaceuticals has a market capitalization of $205.08 million and generates $29.10 million in revenue each year. The biotechnology company earns $-26,750,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Pieris Pharmaceuticals employs 107 workers across the globe.View Additional Information About Pieris Pharmaceuticals.

The official website for Pieris Pharmaceuticals is http://www.pieris.com/.

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected]